
AbbVie Terminates its License Agreement with Molecular Partners for Abicipar Pegol
Shots: AbbVie has terminated the license agreement for abicipar pegol to treat nAMD and DME. Additionally, Molecular Partners will reacquire the development and commercial rights […]